Eye drop delivery of nano‐polymeric micelle formulated genes with cornea‐specific promoters

Tong, Yaw Chong; Chang, Shwu Fen; Liu, Chia-Yang; Kao, Winston W.‐Y.; Huang, Chong; Liaw, Jiahorng

doi:10.1002/jgm.1093

Cited by 65 publications

(77 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[112][113][114][115][116][117][118][119] In a recently published review Cholkar and Mitra have discussed in detail about methods for nanomicelle preparation and their applications in ocular drug delivery. 94 Recently, Pepic et al attempted to deliver the dexamethasone-encapsulated Pluronic/chitosan micellar system.…”

Section: Formulation Approaches For Anterior Chamber Deliverymentioning

confidence: 99%

“…Following topical drop administration, the gene-encapsulated polymeric micellar system improved the mRNA levels of bcl-x(L) by 2.2-fold and reduced corneal apoptosis. 115 From these studies, it is evident that an aqueous nanomicellar formulation of drug or genes can improve permeability in anterior tissues.…”

Section: Formulation Approaches For Anterior Chamber Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Novel Strategies for Anterior Segment Ocular Drug Delivery

Cholkar

Patel

Vadlapudi

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

152

107

View full text Add to dashboard Cite

Research advancements in pharmaceutical sciences have led to the development of new strategies in drug delivery to anterior segment. Designing a new delivery system that can efficiently target the diseased anterior ocular tissue, generate high drug levels, and maintain prolonged and effective concentrations with no or minimal side effects is the major focus of current research. Drug delivery by traditional method of administration via topical dosing is impeded by ocular static and dynamic barriers. Various products have been introduced into the market that prolong drug retention in the precorneal pocket and to improve bioavailability. However, there is a need of a delivery system that can provide controlled release to treat chronic ocular diseases with a reduced dosing frequency without causing any visual disturbances. This review provides an overview of anterior ocular barriers along with strategies to overcome these ocular barriers and deliver therapeutic agents to the affected anterior ocular tissue with a special emphasis on nanotechnology-based drug delivery approaches.

show abstract

Section: Formulation Approaches For Anterior Chamber Deliverymentioning

confidence: 99%

Section: Formulation Approaches For Anterior Chamber Deliverymentioning

confidence: 99%

Novel Strategies for Anterior Segment Ocular Drug Delivery

Cholkar

Patel

Vadlapudi

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

152

107

View full text Add to dashboard Cite

show abstract

“…The core-shell structure may notably enhance the apparent aqueous solubility, leading to a greater concentration gradient favourable for diffusion, and also provide sustained release since the dilution factor in the lachrymal fluid is less than in other administration routes [16]. Polymeric micelles have been shown to be suitable ocular carriers for anti-inflammatory drugs [17] or even plasmids and genes [18,19]. Transcorneal permeation studies through excised rabbit cornea indicated that non-steroidal anti-inflammatory drug formulations in polymeric micelles can enhance about twofold drug permeation compared with that of an aqueous suspension of the same concentration because the dissolution step is overcome [17].…”

Section: Introductionmentioning

confidence: 99%

Single and mixed poloxamine micelles as nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy

Ribeiro

Sosnik

Chiappetta

et al. 2012

J. R. Soc. Interface.

View full text Add to dashboard Cite

Polymeric micelles of single and mixed poloxamines (Tetronic) were evaluated regarding their ability to host the antiglaucoma agent ethoxzolamide (ETOX) for topical ocular application. Three highly hydrophilic varieties of poloxamine (T908, T1107 and T1307) and a medium hydrophilic variety (T904), possessing a similar number of propylene oxide units but different contents in ethylene oxide, were chosen for the study. The critical micellar concentration and the cloud point of mixed micelles in 0.9 per cent NaCl were slightly greater than the values predicted from the additive rule, suggesting that the co-micellization is hindered. Micellar size ranged between 17 and 120 nm and it was not altered after the loading of ETOX (2.7-11.5 mg drug g -1 poloxamine). Drug solubilization ability ranked in the order: T904 (50-fold increase in the apparent solubility) . T1107 ffi T1307 . T908. Mixed micelles showed an intermediate capability to host ETOX but a greater physical stability, maintaining almost 100 per cent drug solubilized after 28 days. Furthermore, the different structural features of poloxamines and their combination in mixed micelles enabled the tuning of drug release profiles, sustaining the release in the 1-5 days range. These findings together with promising hen's egg test-chorioallantoic membrane biocompatibility tests make poloxamine micelles promising nanocarriers for carbonic anhydrase inhibitors in the treatment of glaucoma.

show abstract

“…Os polímeros biodegradáveis apresentam vantagens sobre os não-biodegradáveis, pois não necessitam ser removidos cirurgicamente após o término de sua ação [2] . A versatilidade proporcionada pelos polímeros sintéticos permite obter micropartículas com perfis de liberação específicos possibilitando administrar por diversas vias de administração [10,11] , como parenteral [15] , oral [16] ou oftálmica [17] .…”

Section: Evaporação E/ou Extração Do Solvente Do Meio De Emulsões Do unclassified

Polímeros sintéticos biodegradáveis: matérias-primas e métodos de produção de micropartículas para uso em drug delivery e liberação controlada

et al. 2011

View full text Add to dashboard Cite

Resumo: Micropartículas produzidas a partir de polímeros sintéticos têm sido amplamente utilizadas na área farmacêutica para encapsulação de princípios ativos. Essas micropartículas apresentam as vantagens de proteção do princípio ativo, mucoadesão e gastrorresistência, melhor biodisponibilidade e maior adesão do paciente ao tratamento. Além disso, utiliza menores quantidade de princípio ativo para obtenção do efeito terapêutico proporcionando diminuição dos efeitos adversos locais, sistêmicos e menor toxidade. Os polímeros sintéticos empregados na produção das micropartículas são classificados biodegradáveis ou não biodegradáveis, sendo os biodegradáveis mais utilizados por não necessitam ser removidos cirurgicamente após o término de sua ação. A produção das micropartículas poliméricas sintéticas para encapsulação tanto de ativos hidrofílicos quanto hidrofóbicos pode ser emulsificação por extração e/ou evaporação do solvente; coacervação; métodos mecânicos e estão revisados neste artigo evidenciando as vantagens, desvantagens e viabilidade de cada metodologia. A escolha da metodologia e do polímero sintético a serem empregados na produção desse sistema dependem da aplicação terapêutica requerida, bem como a simplicidade, reprodutibilidade e factibilidade do aumento de escala da produção. Palavras-chave: Polímeros, micropartículas, liberação controlada, métodos de produção. Biodegradable Synthetic Polymers: Raw-Materials and Production Methods of Microparticles for Drug Delivery and Controlled ReleaseAbstract: Microparticles produced from synthetic polymers have been widely used in the pharmaceutical field for encapsulation of drugs. These microparticles show several advantages such as drug protection, mucoadhesion, gastro-resistance, improved bioavailability and increased patient's compliance. In addition, it is possible to use lower amount of drug to achieve therapeutic efficiency with reduced local/ systemic adverse side effects and low toxicity. Synthetic polymers used for the production of microparticles are classified as biodegradable or non-biodegradable, being the former more popular since these do not need to be removed after drug release. Production of polymeric microparticles can be used for encapsulation of hydrophilic and hydrophobic drugs, by emulsification following solvent extraction/ evaporation, coacervation, methods that are revised in this paper, including advantages, disadvantages and viability of each methodology. Selection of methodology and synthetic polymer depends of the therapeutic purpose, as well as simplicity, reproducibility and possibility to scale up. Keywords: Polymers, microparticles, controlled release, production processes. IntroduçãoPolímeros sintéticos têm sido amplamente empregados para a produção de micropartículas de estrutura matricial (microesferas) ou vesicular (microcápsula) para veiculação de fármacos, proteínas e peptídeos [1] . As vantagens obtidas com o uso das micropartículas poliméricas sintéticas são proteção do princípio ativo [2] , mucoadesão [3][4][5] ; ga...

show abstract

Eye drop delivery of nano‐polymeric micelle formulated genes with cornea‐specific promoters

Cited by 65 publications

References 36 publications

Novel Strategies for Anterior Segment Ocular Drug Delivery

Novel Strategies for Anterior Segment Ocular Drug Delivery

Single and mixed poloxamine micelles as nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy

Polímeros sintéticos biodegradáveis: matérias-primas e métodos de produção de micropartículas para uso em drug delivery e liberação controlada

Contact Info

Product

Resources

About